Sunshine Biopharma (SBFM) Assets Average (2016 - 2025)
Sunshine Biopharma's Assets Average history spans 12 years, with the latest figure at $30.8 million for Q4 2025.
- For Q4 2025, Assets Average rose 1.57% year-over-year to $30.8 million; the TTM value through Dec 2025 reached $30.8 million, up 1.57%, while the annual FY2025 figure was $30.3 million, 4.72% up from the prior year.
- Assets Average reached $30.8 million in Q4 2025 per SBFM's latest filing, down from $31.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $41.4 million in Q3 2022 to a low of $1.5 million in Q1 2021.
- Average Assets Average over 5 years is $23.7 million, with a median of $28.9 million recorded in 2023.
- Peak YoY movement for Assets Average: soared 1818.4% in 2022, then plummeted 32.34% in 2023.
- A 5-year view of Assets Average shows it stood at $2.4 million in 2021, then surged by 1390.14% to $35.1 million in 2022, then dropped by 21.55% to $27.5 million in 2023, then rose by 10.22% to $30.3 million in 2024, then increased by 1.57% to $30.8 million in 2025.
- Per Business Quant, the three most recent readings for SBFM's Assets Average are $30.8 million (Q4 2025), $31.7 million (Q3 2025), and $30.6 million (Q2 2025).